Discovery & Development

Research suggests diabetes patients using SGLT-2 and DPP-4 inhibitors have a decreased risk of developing dementia.

We interview Lars Erwig, Director of the Centre of Drug Development at Cancer Research UK, about his career.

Nanorobots developed by engineers from the UK and China have delivered precision treatment to brain aneurysms

A campaign to vaccinate children against polio in Gaza has begun, but success will depend on the vital role of the pharmaceutical industry.

A recent US-based study discovered a new compound that could enhance naloxone’s ability to fend off more potent opioids.

The search for an effective treatment for childhood brain cancers goes on, but a modified Herpes virus could represent a breakthrough.

If used correctly, AI and ML expand our knowledge of biology and vastly improve the speed of success in the clinic.

We speak with the Alzheimer’s Society in the UK about their work. Find out more with The Medicine Maker

NervGen President and CEO Mike Kelly discusses the potential of the company’s investigational drug NVG-291 for spinal cord injury.

CPHI Milan 2024, the premier global event for pharmaceutical professionals, will take place October 8-10 at Fiera Milano.